Q1 EPS Estimate for Bolt Biotherapeutics Boosted by Analyst

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for Bolt Biotherapeutics in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of ($0.34) for the quarter, up from their previous estimate of ($0.41). The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.23) EPS.

A number of other brokerages have also recently weighed in on BOLT. Stifel Nicolaus decreased their price target on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research note on Tuesday. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $1.13.

Bolt Biotherapeutics Stock Performance

Shares of BOLT opened at $0.43 on Friday. The company’s 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.55. The firm has a market cap of $16.29 million, a PE ratio of -0.25 and a beta of 0.94. Bolt Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.56. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.79 million.

Institutional Trading of Bolt Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in Bolt Biotherapeutics during the fourth quarter worth about $25,000. Squarepoint Ops LLC acquired a new position in Bolt Biotherapeutics during the 4th quarter worth approximately $26,000. Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $27,000. Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $42,000. Finally, FMR LLC boosted its stake in shares of Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.